Walk­ing the walk, Al­ny­lam ap­points for­mer FDA head Mar­garet Ham­burg to the board

Right on the heels of an in­dus­try-wide no­tice from BIO to speed up gen­der di­ver­si­ty in the C-suite and board­room, Al­ny­lam is adding to its ros­ter with the ap­point­ment of for­mer FDA com­mis­sion­er Mar­garet Ham­burg to the board.

The let­ter, prompt­ed by a slate of con­tro­ver­sies over the lack of gen­der di­ver­si­ty and in­clu­sion dur­ing high-lev­el con­fer­ences such as JPM and BIO, was signed off by Al­ny­lam CEO John Maraganore, this year’s chair­man, along with Halozyme chief He­len Tor­ley and BIO chief Jim Green­wood.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN